Androgen receptor non-canonical domain binding degrader for treatment of relapsed, refractory castration-resistant prostate cancer: K. Sadasivan Pillai Wednesday, March 5, 2025, 0 ...

Novartis Pharmaceuticals Canada Inc. (Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection) for eligible patients ...

Clinical outcomes of prompt versus deferred 177Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering ...

Eikon Therapeutics, the brainchild of Roger Perlmutter, has raised a total of $1.1 billion since it launched in 2019.

Eikon is pursuing a number of clinical-stage programs including EIK1001, which is currently in Phase III testing for advanced ...

(Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto� (lutetium (177Lu) vipivotide tetraxetan injection) for eligible patients with prostate-specific membrane ...

Androgen receptor gene amplification and over expression ... For many years ketoconazole was the only CYP17 inhibitor that was used to treat mCRPC. However, significant toxicities limit its ...

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...